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1. Introduction  8 
The transmissible spongiform encephalopathies (TSEs) constitute a family of fatal, 9 
neurodegenerative diseases, including scrapie in sheep, chronic wasting disease (CWD) in 10 
deer and elk, bovine spongiform encephalopathy (BSE) and a range of human disorders, such 11 
as Creutzfeldt-Jakob disease (CJD), kuru and fatal familial insomnia. The archetypal TSE 12 
disease is scrapie of sheep and goats, which has been present in the UK flock for over 200 years 13 
as a result of both horizontal and vertical transmission. The most prevalent TSE disease of 14 
humans is sporadic Creutzfeldt-Jakob disease (spCJD), which affects 1-3 individuals per 15 
million worldwide. A new form of CJD, known as variant CJD (vCJD), was diagnosed in 16 
humans in the mid 1990s and it is likely that vCJD was contracted by consumption of 17 
contaminated beef, since this disease is indistinguishable from BSE on transmission to a panel 18 
of mice (Bruce et al., 1997). To date, there have been 175 cases of vCJD in the UK and a further 19 
49 cases across 11 other countries (www.eurocjd.ed.ac.uk, data correct as of Aug 2011).  20 
During pathogenesis of TSE disease the principal molecular event is the conformational 21 
rearrangement of a normal, host protein called the prion protein. The normal form of the 22 
prion protein, PrPC, misfolds to a form known as PrPSc. PrPSc is insoluble and partially 23 
resistant to digestion by proteolytic enzymes that would usually recycle incorrectly folded 24 
proteins. PrPSc therefore accumulates in proteinaceous aggregates, including plaques and 25 
fibrils. The prion protein is ubiquitously expressed, but is most abundant in the central 26 
nervous system (CNS). Hence accumulation of PrPSc occurs principally in the brain, but 27 
peripheral lymphoreticular tissues can also accumulate proteinaceous deposits. The prion 28 
hypothesis suggests that PrPSc is the infectious agent in TSE diseases and that it catalytically 29 
causes nascent PrPC molecules also to misfold (Prusiner, 1998). TSEs exist as discrete strains 30 
of disease, which can be stably passaged in suitable hosts resulting in differences in 31 
incubation time, clinical signs and pathology. It is suggested that PrPSc exists in different 32 
conformations, which encode the information necessary to transmit each disease and cause 33 
the strain-specific pathology (Prusiner, 1998). As a result of the critical involvement of the 34 
prion protein in TSEs, these disorders are also known as prion diseases. 35 
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At clinical end point of TSE disease, there is characteristic vacuolation in various areas of the 1 
brain, the exact locations of which depends on the infecting strain. Loss of neurons can also 2 
be detected at late stages of disease as can alterations in membrane morphology. Several 3 
excellent reviews cover neuropathology of animal (Jeffrey et al., 2011) and human (Kovacs & 4 
Budka, 2009) diseases that is evident on post mortem examination. In general, there are 5 
good correlations between disease, neurodegeneration and prion protein aggregation in 6 
many TSE diseases, which has led to suggestions that PrPSc-containing aggregates are 7 
directly toxic to neurons. In vitro studies largely support this conjecture, but the evidence in 8 
vivo is less convincing. Even assuming that a misfolded form of the prion protein is 9 
responsible for neurotoxicity, the mechanisms that initiate the cascade leading to neuronal 10 
loss are unknown. It is also unknown whether loss of function of PrPC, as it is sequestered 11 
from the cell surface into proteinaceous aggregates, plays a role in rendering neurons 12 
susceptible to degeneration. Reactive astrocytosis is evident during the clinical phase and 13 
whilst time course studies have also suggested that astrocytes are activated at earlier stages, 14 
it is not known to what these cells are responding. In this chapter we review briefly the state 15 
of knowledge of the processes leading the neurodegeneration in TSE diseases, with a 16 
particular focus on the earliest detectable events.  17 
2. Early morphological events in TSE-induced neuronal loss 18 
In both prion diseases and other neurodegenerative disorders, the mechanisms leading to 19 
neurodegeneration remain particularly poorly understood. As mentioned above, the clinical 20 
phase of a variety of natural prion diseases has been studied, which has produced 21 
descriptions of the targeting of pathology, including the localisation of PrPSc deposits and of 22 
characteristic vacuolation and spongiform alterations. Substantial neuronal loss occurs by 23 
terminal endpoint, but it has become clear that loss of neurons is a relatively late 24 
development in the progression of pathology. In common with other neurodegenerative 25 
diseases, at later time points there are characteristic abnormalities in a range of normal 26 
neuronal molecular processes; this includes defects in ion homeostasis, aberrant 27 
mitochondrial morphologies and function, increased production of reactive oxygen species, 28 
endoplasmic reticulum stress and reduced proteasome function. Many of these homeostatic 29 
defects are thought to drive each other and it is therefore not clear which, if any, is the 30 
initiating factor. Thus, gross defects in several biochemical pathways represent the end 31 
stages of disease, but to determine causal mechanisms, it is necessary to describe in 32 
molecular and morphological detail the earliest stages of the neurodegenerative process. In 33 
naturally-contracted diseases, such descriptive studies are frequently not possible because 34 
(i) it is difficult to diagnose disease in advance of clinical signs (ii) outbred animals and 35 
humans can show significant variability in specific responses to disease and (iii) it is often 36 
impossible to know how and when individuals became infected. To remedy this situation, 37 
much use has been made of rodents as models of prion disease; C57BL/6 mice infected with 38 
the ME7 murine scrapie strain is the experimental system that has been studied in the 39 
greatest detail. There are clear advantages in using experimental prion diseases as a model, 40 
since the disease begins and ends at defined points (inoculation and death) and the 41 
homogeneity afforded by inbreeding produces standardised results. One caveat to murine 42 
models is that it appears that not all aspects of TSE disease in rodents are replicated in 43 
natural disease of large animals (Jeffrey et al., 2011). Nevertheless, some key findings from 44 
study of ME7 infection of mice are depicted graphically in Figure 1 and discussed below. 45 
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 1 
Fig. 1. Schematic timeline, in weeks, of pathological and behavioural events during infection 2 
of C57BL/6 mice with the mouse-passaged prion stain ME7. Information contained in this 3 
figure has been abstracted from multiple publications, referenced in section 2. 4 
2.1 Synaptic degeneration precedes neuronal loss in prion disease 5 
Recent studies of the pathogenesis of the ME7 strain of murine scrapie have allowed the 6 
identification of synaptic deficits within the hippocampus of C57BL/6 mice that occur well 7 
before neuronal loss can be observed (Betmouni et al., 1999, Cunningham et al., 2003, 8 
Guenther et al., 2001, Jeffrey et al., 2000). From roughly half way though the incubation 9 
period, synaptic deficits can be characterised at a molecular level by a loss of integral 10 
synaptic vesicle proteins and reduced synaptophysin staining (Cunningham, et al., 2003, 11 
Cunningham et al., 2005, Gray et al., 2009). Importantly, molecular changes appear to 12 
correlate with functional deficits, since electrophysiological abnormalities have also been 13 
observed within a similar timeframe (Chiti et al., 2006). At week 12, an accumulation of 14 
electron rich material within the pre-synapse in the CA1 region of the hippocampus was 15 
observed by use of electron microscopy, specifically between CA3 pre-synapses and CA1 16 
post-synaptic densities within the Schaffer-Collateral pathway (Siskova et al., 2009). As the 17 
disease progressed, a distinct curvature of the post-synaptic densities around the 18 
degenerating pre-synapses could be visualised (Siskova, et al., 2009), potentially an attempt 19 
to maximise synaptic transmission. In addition, a loss of perineuronal nets surrounding 20 
GABAergic interneurons of the hippocampus coincided with a reduction in synaptic 21 
plasticity at early time-points (week 11/12) (Franklin et al., 2008). Early synaptic changes are 22 
a feature of other strains of murine disease, suggesting that these events may be early 23 
pathological markers of a TSE infection (Siso et al., 2002), at least in rodents. Synaptic 24 
dysfunction also appears to be a consistent, early pathological sign in many other 25 
neurodegenerative diseases, but there are suggestions that the exact morphological changes 26 
seen may differ depending on whether the insults to synapses are caused by processes 27 
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leading to intra- or extra-cellular protein deposits. In addition, synaptic dysfunction in prion 1 
diseases differs from that seen during Wallerian degeneration in the periphery, in which 2 
axons are dissected or otherwise compromised and presynapses retract (Gillingwater et al., 3 
2003). In prion diseases, loss of synapses appears to be followed by a retraction of the 4 
dendritic spine, but whether loss of any given synapse impacts on neighbouring synapses 5 
and ultimately on the respective cell body remains to be determined.  6 
The early loss of synapses in prion disease must occur in response to a disease-associated 7 
molecular event or biochemical pathway. It is possible that this event may be the beginnings 8 
of the misfolded protein cascade, since in C57BL/6 mice infected with ME7 scrapie the 9 
accumulation of PrPSc can be detected at week 8, before the first observable signs of synaptic 10 
defects. The first deposits of abnormal PrP accumulate in the dentate gyrus of the 11 
hippocampus, subsequently spreading to encompass the CA3 sub-region of the 12 
hippocampus (Gray, et al., 2009). This suggests a progression of PrPSc formation along the 13 
Mossy-Fibre pathway, connecting the dentate gyrus and CA3 field, and a subsequent 14 
pathological dysfunction of CA3 neurons leading to degeneration of CA3 pyramidal cell 15 
pre-synapses in the CA1 region along the Schaffer-Collateral pathway. In the majority of 16 
prion diseases that have been studied in detail, PrPSc accumulation is one of the earliest 17 
detectable pathological signs and precedes, or is concurrent with, cellular or synaptic 18 
changes. These results suggest a causative correlation between the initial signs of PrP 19 
conversion and synaptic dysfunction. This raises the question of whether neurodegenerative 20 
processes are also similar in other prion disease models, particularly those that have small 21 
quantities of misfolded PrP present at the clinical end point (Barron et al., 2007). In the 22 
majority of cases, time course studies of such disease models have not been performed in 23 
sufficient detail to dissect the earliest pathological events. It is clear, nevertheless, that 24 
synaptic dysfunction and degeneration occur well before neuronal loss is observed in TSEs.  25 
2.2 The role of glia in prion disease-induced neurodegeneration 26 
Although neuronal death in TSEs is the most widely recognised pathological manifestation 27 
at a cellular level, alterations in non-neuronal cells are also apparent occurring alongside the 28 
first obvious signs of PrPSc accumulation in the brain. Reactive astrogliosis, exemplified by 29 
up regulation of Gfap, can be seen in various areas of the brain (Betmouni et al., 1996, 30 
Cunningham, et al., 2003). An increased understanding of astrocytes suggests that these cells 31 
have an integral role in maintaining homeostatic functions within the CNS (Butt et al., 1994, 32 
Chang Ling & Stone, 1991, Ransom et al., 2003, Robinson & Dreher, 1989, Slezak & Pfrieger, 33 
2003). Astrocytic processes come into close contact with synapses (Bushong et al., 2004, 34 
Grosche et al., 1999) forming a ‘tripartite’ between the pre and post synaptic elements and 35 
the fine astrocytic processes (Araque et al., 2009). Astrocytes can undergo excitatory 36 
mediated release of chemical neurotransmitters as a result of increases of intracellular Ca2+ 37 
concentrations in the astrocyte cytoplasm (Kreft et al., 2009). Reactive astrogliosis is thought 38 
to play a neuroprotective role during acute brain injuries, for example during cerebral 39 
ischemia (Pekny et al., 2008), but it is not clear whether the activation of astrocytes is also 40 
neuroprotective during chronic infections, such as TSE diseases.  41 
Microglia also exhibit an activated morphology prior to and concurrent with 42 
neurodegeneration, however, this doesn’t appear to represent the classic inflammation one 43 
may expect during infection with classical pathogens (Perry et al., 2002). Instead, a concept 44 
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of ‘microglial priming’ is thought to occur. Activated microglia produce an anti-1 
inflammatory phenotype in response to ongoing TSE pathology, but subsequent systemic 2 
insults can elicit a rapid inflammatory response, initially by increases in IL-1β (Perry et al., 3 
2007, Perry et al., 2003). Since the microglial response is not associated with classic 4 
inflammation, the role that these cells play in neurodegenerative disease remains unknown. 5 
It has been hypothesised that microglia have a neurotoxic role in neurodegeneration (Block 6 
et al., 2007) but other studies suggest microglia could be neuroprotective (Solito et al., 2010). 7 
There are also suggestions that microglia are not involved in the neurodegenerative process 8 
at all, but that degeneration is a neuron-autonomous process, at least at early stages (Perry & 9 
O'Connor, 2010). For both astrocytes and microglia, it remains unknown what these cells are 10 
responding to and whether this response aids or is detrimental to neuronal health. 11 
However, their activation at around the time that PrPSc deposition can first be observed 12 
suggests that they respond to the ongoing conversion process, to the accumulation of PrPSc 13 
itself or to the changes that PrP conversion and/or PrPSc deposition elicits in cellular 14 
mechanisms or synaptic morphology, plasticity and function. Mice in which PrPC expression 15 
is restricted to astrocytes are susceptible to TSE infection (Raeber et al., 1997) suggesting that 16 
these cells are important in replication of PrPSc as well as in responding to its presence. In 17 
many studies using the ME7 murine scrapie strain, there exists strong correlations between 18 
the initial accumulation of PrPSc and neurodegeneration suggesting a key role for misfolded 19 
PrP in the mechanism of neuronal degeneration. This raises the key question of whether 20 
abnormal PrP isoforms are neurotoxic and, if so, what their molecular structures are. 21 
3. Molecular mechanisms underlying degeneration of neurons 22 
Prion protein deficient mice are resistant to TSE infection (Bueler et al., 1993, Manson et al., 23 
1994b), demonstrating that PrPC is required for disease. However, it is unclear what 24 
property of PrP is important for pathology: whether the PrPSc that accumulates during 25 
disease is actually toxic to neurons directly, whether the loss of PrPC plays a role in 26 
rendering neurons susceptible to toxic insults (either involving PrPSc or not) or whether the 27 
ongoing process of agent replication compromises normal neuronal homeostasis. Although 28 
PrPSc accumulation appears to precede neuronal loss in ME7 scrapie, there are reasons to 29 
suggest that the accumulation of misfolded PrP is not responsible for neurotoxicity directly. 30 
For example (i) neurons which lack PrPC do not degenerate in the presence of infected graft 31 
tissue rich in PrPSc (Brandner et al., 1996) and (ii) a variety of models exist in which levels of 32 
PrPSc and neuronal loss are poorly correlated (Barron, et al., 2007, Baumann et al., 2007, 33 
Chiesa et al., 1998, Flechsig et al., 2003, Hegde et al., 1998, Lasmezas et al., 1997, Li et al., 34 
2007, Ma et al., 2002, Muramoto et al., 1997, Piccardo et al., 2007, Shmerling et al., 1998). But 35 
if classical PrPSc is not neurotoxic, then what is the toxic species? 36 
3.1 Neurotoxicity of different aberrantly folded PrP isoforms 37 
Considerable morphological heterogeneity can be observed in the protein deposited in vivo 38 
and recombinant PrP (recPrP) also exhibits conformational flexibility in vitro. There are also 39 
reports of aberrant cell biological behaviour of PrPC at various stages of its cellular life-cycle, 40 
as depicted in figure 2, and these factors make pinpointing the neurotoxic entity rather 41 
challenging. Recent studies seem to support the idea that relatively small, (pre-fibrillar?) 42 
oligomeric protein species are highly neurotoxic (Bucciantini et al., 2002, Caughey & 43 
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Lansbury, 2003, Novitskaya et al., 2006, Simoneau et al., 2007, Zhang et al., 2010) and this 1 
appears true not just for prion diseases but also for other neurodegenerative protein 2 
misfolding diseases, further suggesting that common mechanisms of neurodegeneration 3 
may exist. RecPrP preparations have been used to investigate what the mechanisms 4 
underlying neuronal death may be, but in vitro studies such as these come with their own 5 
set of limitations. Nevertheless, a consensus from several studies suggests that oligomeric 6 
protein assemblies physically disrupt cellular membranes affecting the calcium levels within 7 
the cell (Sanghera et al., 2008, Simoneau, et al., 2007, Zhang, et al., 2010). This may occur by 8 
the insertion of oligomers into the phospholipid membrane (Kayed et al., 2004) and, since 9 
the plasma membrane is accessible to both intracellular and extracellular proteins, 10 
perturbation of the membrane may provide a mechanistic link between protein misfolding 11 
diseases that are associated with either intra- or extracellular deposits. An alternative theory 12 
is that functional structures, composed of oligomeric proteins, form within the lipid bilayer. 13 
These structures appear to act as relatively porous ion channels, affecting the cellular 14 
membrane potential and ionic homeostasis, leading to apoptosis (Quist et al., 2005).  15 
In contrast to oligomers, fibrillar aggregates of recPrP have shown variable toxicity in vitro: 16 
some researchers have found that fibrils are not toxic to cells (Simoneau, et al., 2007), 17 
suggesting that fibril formation in vivo is a protective mechanism or an “end-point” in the 18 
misfolding pathway (Caughey & Lansbury, 2003, Silveira et al., 2005). Conversely, other 19 
studies have shown fibrils to be just as toxic as oligomers (Novitskaya, et al., 2006), but since 20 
protein preparations are generally not extensively characterised prior to incubation with 21 
cells in vitro, it is possible that differences in protein structure may account for these 22 
inconsistencies. Although fibrils are typically perceived to be rather inert, it is also 23 
conceivable that smaller species could fragment from fibrillar aggregates, which may then 24 
possess the neurotoxic properties of oligomers (Tanaka et al., 2006). A study using Aβ fibrils 25 
showed that interaction of the fibrils with lipids led to fragmentation, forming oligomers 26 
which were highly toxic (Martins et al., 2008). Thus the toxicity of amyloid fibrils may be 27 
inversely proportional to their stability. However, Novitskaya et al. showed that fibrils 28 
composed of recPrP caused cells to aggregate and subsequently undergo apoptosis, an effect 29 
that wasn’t seen for oligomers in the same experiments (Novitskaya, et al., 2006). This 30 
aggregation was reduced when PrPC was down-regulated, suggesting a role for PrPC in 31 
mediating toxicity. There have also been recent reports that PrPC is required for the toxicity 32 
exhibited by a range of molecular species (Resenberger et al., 2011a).  33 
PrPC is expressed heavily at synapses and the misfolding process may initiate in and around 34 
the synaptic cleft. This localises all relevant molecular species in the compartment in which 35 
the first morphological changes are detected, but this is still someway short of proving that 36 
abnormal PrP is neurotoxic. Through ongoing studies in our laboratories, we are 37 
endeavouring to dissect the relationship between PrPSc, infectivity, neurotoxicity and 38 
mechanisms of neurodegeneration (Barron, et al., 2007, Bradford et al., 2009, Cancellotti et 39 
al., 2010, Cancellotti et al., 2005, Manson et al., 2001, Piccardo, et al., 2007, Tuzi et al., 2008, 40 
Tuzi et al., 2004). Through the use of several unique models of prion disease in mice, we are 41 
beginning to accumulate evidence suggesting that the levels of infectivity are not always 42 
dependent on the quantity of misfolded PrP present (Barron, et al., 2007, Piccardo, et al., 43 
2007). In conjunction with studies on the neurotoxicity of misfolded recombinant prion 44 
proteins, this leads to the theory that specific subpopulations of PrP conformations represent 45 
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either the infectious or neurotoxic agents of TSEs (Weissmann, 1991). The role of PrPC in 1 
neuronal toxicity is still controversial and prompts the question of whether a reduction in 2 
the levels of PrPC on the cell surface, as it is converted into PrPSc, is a critical factor in prion 3 
disease-specific neurodegeneration. 4 
Secretory 
trafficking 
vesicles
ERAD
Endosomal 
pathway
Lipid raft
Mitochondria
Proteasome
Amorphous 
aggregate
Over-
expression
Oligomers
A
B
C
D
E
F
G
Fibril
 5 
Fig. 2. Normal cell biology and putative misfolding pathways of PrP leading to toxicity. The 6 
prion protein is expressed in the secretory pathway and, after transiting the endoplasmic 7 
reticulum and Golgi apparatus, the protein is trafficked to the cell surface (A). Here it resides in 8 
specialised microdomains known as lipid rafts (B) but must move out of these domains to 9 
undergo endocytosis (C), presumably mediated by a cell surface receptor. After endocytosis 10 
PrPC is routed on the endosomal pathway (D). Both the cell surface and the endosomal pathway 11 
have emerged as candidate locations for prion protein misfolding to intra- and/or extra-cellular 12 
oligomers or fibrils. After trafficking through endosomes, a proportion of the protein can be 13 
degraded, whilst some of it is routed back to the cell surface (E). Over-expression of PrPC results 14 
in its localisation in mitochondria (F) whilst blockade of proteasome function leads to 15 
cytoplasmic accumulation (G). Both processes may follow retrograde transport of PrP from the 16 
ER by endoplasmic reticulum associated degradation (ERAD) processes. 17 
3.1 Does loss of PrP
C
 function play a role in neurodegeneration?  18 
The failure to infect prion protein knockout mice demonstrated conclusively that PrPC is 19 
needed to sustain prion disease (Bueler, et al., 1993, Manson, et al., 1994b). These animals 20 
were also expected to inform on PrP function, but initial observations suggested that 21 
knockout mice developed normally (Bueler et al., 1992, Manson et al., 1994a). More in depth 22 
studies have highlighted a range of subtle and not so subtle alterations, including abnormal 23 
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circadian rhythms (Tobler et al., 1996), defects in long term potentiation (Curtis et al., 2003, 1 
Maglio et al., 2006) and abnormalities of mitochondrial numbers and morphologies (Miele et 2 
al., 2002). From additional studies, primarily in cells lacking PrPC, there have been 3 
suggestions that PrPC has roles in copper binding and trafficking (Brown et al., 1997), the 4 
response to reactive oxygen species (Brown et al., 1999), neuritogenesis (Graner et al., 2000, 5 
Lopes et al., 2005) and calcium homeostasis (Colling et al., 1996, Fuhrmann et al., 2006, 6 
Herms et al., 2001). A key recent finding in PrPC knockout mice was defects in the 7 
maintenance of the myelin sheath surrounding peripheral nerves, a phenotype that 8 
appeared specifically to result from depletion of PrPC from neurons (Bremer et al., 2010). 9 
Thus, prion protein knockout mice have a range of physiological phenotypes primarily 10 
related to neuronal functions and this has led to a consensus that PrPC is a neuroprotective 11 
molecule, although it is not clear how, specifically, this neuroprotection is manifest 12 
(Resenberger et al., 2011b). A thorough review of prion protein function is beyond the scope 13 
of this chapter but, in the context of TSE disease, a key question is whether the loss of a 14 
neuroprotective function of PrPC plays a role in neurodegenerative mechanisms. Some 15 
intriguing observations came from experiments in which tissue from PrP-expressing mice 16 
was grafted into the brains of PrP knockout mice. After intracerebral prion infection, the 17 
grafted tissue developed pathology typical of prion disease, including PrPSc deposition, 18 
neuronal loss and vacuolation (Brandner, et al., 1996). However, despite PrPSc spreading 19 
from the grafted tissue into the surrounding brain area, no loss of PrP-null neurons was 20 
observed. These data strongly suggest that PrPSc is not neurotoxic in the absence of PrPC 21 
expression in neurons, results that were backed up by experiments in which PrPC expression 22 
in neurons was conditionally turned off in mice during an ongoing prion infection (Mallucci 23 
et al., 2003). Further evidence comes from infection of PrPC-GPI-/- mice (discussed further 24 
below), which do not express PrPC on the surface of neurons or indeed any neural cells 25 
(Chesebro et al., 2005). In GPI-/- mice, significant levels of PrPSc accumulated during disease 26 
but neuronal loss was not observed. These lines of evidence suggest that PrPC loss does not 27 
play a role in neurotoxicity and actually suggests the contrary – that normal neuronal PrPC 28 
expression is required for neurotoxicity (Resenberger, et al., 2011a). 29 
Contradictory evidence comes from studies in PrPC-null mice transgenically expressing 30 
hamster PrPC exclusively on astrocytes; these mice were capable of supporting hamster-31 
passaged prion disease and developed clinical signs, indicating that neuronal PrPC was not 32 
necessary for neuronal degeneration (Raeber et al., 1997). In the same studies, astrocytic 33 
hamster PrPC was expressed in mice in addition to wild type murine PrPC and these mice 34 
propagated hamster prion infectivity but did not develop disease, suggesting a role for 35 
mouse PrPC in protecting neurons from the toxicity of PrPSc. There are also several studies 36 
demonstrating that the toxicity of prion-related polypeptides is independent of the 37 
expression of PrPC on neurons. Hence, the role of PrPC in neurotoxicity is not clear and 38 
further understandings of how misfolded proteins can lead to synaptic degeneration and/or 39 
neurodegeneration will require a closer relationship between in vivo and in vitro studies. It 40 
seems likely that the initiation and progression of pathology leading from synaptopathy to 41 
neuronal loss requires a combination of (i) interaction of PrPSc with the synaptic 42 
membrane/vesicle membranes (ii) ongoing PrPSc propagation (iii) loss of PrPC function and 43 
(iv) extracellular toxic PrPSc deposits. Since misfolding of PrP is required for the pathology 44 
associated with TSE disease, understanding the factors that aid this process will also aid our 45 
understanding of neurotoxicity and neuronal loss. 46 
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4. The mechanisms of prion protein misfolding leading to neuronal loss 1 
The prion protein is an obligatory component of TSE disease and its misfolding appears 2 
central to disease pathogenesis. Understanding how protein misfolding leads to pathology 3 
is of crucial importance but it is extremely challenging to study mechanistic aspects of 4 
protein folding and misfolding in vivo, hence in vitro studies have contributed almost all 5 
knowledge that currently exists in this area. This has involved solving and/or modelling 6 
structures of normal and aberrant forms of PrP and modelling the structural transition. The 7 
normal form of the protein has been investigated by use of recombinant prion proteins 8 
expressed in prokaryotic systems and refolded in vitro. The atomic level structures of such 9 
isoforms have been defined by both nuclear magnetic resonance (NMR) spectroscopy, for a 10 
range of different prion proteins e.g. (Calzolai et al., 2005, Christen et al., 2008, Gossert et al., 11 
2005, Lysek et al., 2005, Perez et al., 2010, Wuthrich & Riek, 2001), and X-ray crystallography 12 
for sheep (Eghiaian et al., 2004, Haire et al., 2004) human (Antonyuk et al., 2009, Knaus et al., 13 
2001, Lee et al., 2010) and rabbit proteins (Khan et al., 2010). These studies found that the C-14 
terminal region of PrP has globular structure (depicted in Fig 3) and NMR investigations of 15 
native PrPC purified from cattle brains confirmed these structural assignments (Hornemann 16 
et al., 2004).   17 
 18 
Fig. 3. The tertiary structure of PrPC with two average sized N-linked glycans added at the 19 
two N-linked consensus sites (human numbering), to scale, demonstrating the contribution 20 
that these moieties make to the total volume of the prion protein 21 
By contrast, the N-terminal region appears dynamically disordered. This domain incorporates 22 
4-5 glycine-rich octapeptide repeats, which bind copper ions in vitro (Nadal et al., 2009, 23 
Pauly & Harris, 1998, Whittal et al., 2000, Wong et al., 2000a) and possibly in vivo (Brown, et 24 
al., 1997, Waggoner et al., 2000) and the region also mediates the binding of PrPC to 25 
polyanionic compounds (Brimacombe et al., 1999). Although the N-terminal domain has 26 
been reported to be flexibly disordered, there have also been several reports of polyproline 27 
Asn181 
Asn197 
C-terminus 
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II structure in this region (Blanch et al., 2004, Gill et al., 2000, Taubner et al., 2010). The N-1 
terminal region is present in the majority of PrPSc in diseased brains (Hope et al., 1986), but 2 
it seems to be dispensable for disease-specific misfolding, since transgenic mice expressing 3 
protein lacking the N-terminal domain are fully susceptible to disease (Fischer et al., 1996). 4 
The globular C-terminal region incorporates two consensus sites for N-linked glycosylation, 5 
a single disulphide bond and a glycosylphosphatidyl inositol (GPI) membrane anchor is 6 
appended to the extreme C-terminus. After conversion of PrPC to PrPSc, the C-terminal 7 
domain is resistant to protease digestion, indicating that it is this section of the protein that 8 
undergoes conformational change during prion protein misfolding. 9 
By contrast to PrPC, atomic level detail of PrPSc tertiary structure is lacking, which is a result 10 
of the insolubility of PrPSc-containing aggregates and the heterogeneity of morphologies of 11 
these aggregates. The structure of PrPSc has been probed by use of several low resolution 12 
techniques and Fourier-transform infra red (FT-IR) spectroscopic analysis suggests that the 13 
transition from PrPC to PrPSc is associated with a partial increase in β-sheet structure 14 
(Caughey et al., 1991). Initially it was proposed that the second and third α-helices are not 15 
misfolded and theoretical structures followed, the most detailed of which is based upon 16 
empirical structural investigations by electron crystallography (Govaerts et al., 2004, Wille et 17 
al., 2002). However, recent data from hydrogen/deuterium-exchange experiments in 18 
conjunction with mass spectrometry has cast doubt on the existence of α-helical sections in 19 
PrPSc (Smirnovas et al., 2011). Instead, H/D exchange rates in PrPSc appear consistent with 20 
formation of β-sheet across the entire C-terminal domain, a result that challenges 21 
conventional wisdom of PrPSc structure. The problems associated with solving the structure 22 
of PrPSc appear insurmountable, at least at the present time and we are more likely to derive 23 
useful information from reasonable models of PrPSc. 24 
4.1 Misfolding of PrP can be modelled in vitro 25 
The structural transition from PrPC to PrPSc can be mimicked in vitro by a variety of 26 
techniques and this has allowed various determinants of protein misfolding to be 27 
investigated. By mixing together PrPSc and recPrP expressed in mammalian cell lines to 28 
result in newly protease resistant PrP (PrPRes) the group of Byron Caughey showed that 29 
PrPSc can auto-catalytically seed the conformational conversion of recPrP (Kocisko et al., 30 
1994). This technique was termed the cell free conversion assay (CFCA) and it was 31 
subsequently shown to mimic many aspects of disease seen in vivo, including species 32 
barriers (Kirby et al., 2003, Kocisko et al., 1995) and the inhibitory effects of specific 33 
chemicals (Caughey et al., 1998, Demaimay et al., 2000, Demaimay et al., 1998). Quantifying 34 
conversion efficiency allows insights into mechanistic aspects of conversion: for example, 35 
there are two distinct phases of prion protein conversion – binding followed by 36 
conformational alteration (Horiuchi & Caughey, 1999) – and single amino acid substitutions 37 
were shown to dramatically affect the efficiency of conversion of the substrate (Bossers et al., 38 
1997, Eiden et al., 2011, Kirby et al., 2010, Kirby et al., 2006). Furthermore, use of microsomes 39 
containing PrPSc and PrPC in CFCA reactions indicated that the two proteins must be in the 40 
same vesicle for conversion to take place (Baron et al., 2002).  41 
More recently, a second generation of in vitro prion misfolding assays has arisen, principally 42 
in response to the need for improved prion diagnostics. By the use of exogenous sources of 43 
energy to agitate the classical CFCA reaction, coupled with replenishment of the substrate, 44 
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conversion efficiencies can be dramatically enhanced. Conversion reactions driven by 1 
sonication or shaking have been developed and include methods known as protein misfolding 2 
cyclic amplification (PMCA) (Saa et al., 2006, Saborio et al., 2001), quaking induced conversion 3 
(QuIC) (Atarashi et al., 2011, Atarashi et al., 2008) and amyloid seeding assay (ASA) (Colby et 4 
al., 2007). The PMCA technique has also been shown to be capable of creating prion infectivity 5 
de novo from PrPC substrate in the absence of a PrPSc seed (Castilla et al., 2005). The protocols 6 
for CFCA, PMCA or QuIC assays differ in detail but generic principles underlie all such 7 
assays, as depicted in figure 4. In all cases a catalytic seed of PrPSc causes misfolding of a 8 
substrate, and this phenomenon firmly establishes that auto-catalytic, templated misfolding is 9 
a generic process in prion diseases. In addition to sources of physical energy, believed to aid 10 
fragmentation of large fibrils thereby generating fresh seed, many of the prion amplification 11 
techniques also require facilitation with other factors to amplify both infectivity and misfolded 12 
protein (Deleault et al., 2007, Wang et al., 2010). In this context, it is notable that several 13 
techniques exist to misfold recPrP in the absence of a physiological seed. Pathways leading to 14 
fibrils (Baskakov et al., 2002, Stohr et al., 2011) or oligomers (Rezaei, 2008, Tahiri-Alaoui et al., 15 
2004, Tahiri-Alaoui et al., 2006) have been described, where misfolding is promoted by 16 
partially denaturing conditions. These processes occur comparatively rapidly and generally do 17 
not replicate features of disease, such as species barriers (Makarava et al., 2007) or 18 
polymorphic control of susceptibility (Baskakov et al., 2005, Kirby, et al., 2010), and also do not 19 
appear to generate bona fide prion infectivity (Legname et al., 2004, Makarava et al., 2010). 20 
These lines of evidence argue for a role for molecular cofactors in disease-specific prion protein 21 
misfolding (Birkmann & Riesner, 2008, Gill et al., 2010, Graham et al., 2010). Identifying these 22 
co-factors in vivo will allow significant progress in the prevention of disease transmission. 23 
 
PrPC or 
recPrP 
PrPSc  
+ 
Auxiliary 
cofactors  
(A) 
 24 
Fig. 4. Schematic pathways for seeded conversion of normal PrP to a protease-resistant 25 
isoform. In the absence of auxiliary cofactors, conversion is inefficient and only a small 26 
amount of available substrate is converted (A). This pathway is exemplified by the classic 27 
CFCA. By addition of auxiliary cofactors, conversion efficiency can be improved and 28 
periodic shaking (QuIC) or sonication (PMCA), coupled with replenishment of substrate, 29 
allows cyclic conversion leading to amplification of PrPRes 30 
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4.2 Factors contributing to prion protein misfolding 1 
Dramatic breakthroughs in the search for determinants of the prion protein misfolding 2 
process have been made in recent years. Deleault et al used the PMCA technique to amplify 3 
PrPC that had been highly purified from brain tissue to which polyanionic species (RNA or 4 
glycosaminoglycans) were added. This mixture was sufficient to allow amplification of 5 
abnormal PrP when seeded with PrPSc, but also allowed the generation of abnormal PrP de 6 
novo in the absence of a catalytic seed. Crucially, the newly-synthesised abnormal PrP was 7 
shown to cause a TSE-like disease after inoculation to wild type animals. These data imply 8 
that purified PrPC (along with lipids that co-purified with the protein) in addition to a 9 
polyanionic cofactor are the minimal requirements for creation of prion infectivity (Deleault, 10 
et al., 2007). Various researchers have since replicated or extended this work (Barria et al., 11 
2009, Edgeworth et al., 2010, Weber et al., 2007), culminating in the publication of a study 12 
describing prion infectivity, created de novo, from bacterially-expressed recPrP 13 
supplemented with just synthetic lipid and total RNA extracted from murine liver (Wang, et 14 
al., 2010). What are the identities of molecules playing the roles of cofactors in vivo? 15 
One approach to determine in vivo cofactors is to investigate the aggregates present in prion-16 
infected animals for molecules that may have played a role in their formation. Other than 17 
PrP, various proteinaceous molecules appear specifically enriched in infectious prion fibrils 18 
(Giorgi et al., 2009, Moore et al., 2010, Petrakis et al., 2009) and recent data from our 19 
laboratory suggest that at least one such protein can enhance prion protein conversion 20 
efficiency (Graham et al., 2011). The most likely places for PrPC to encounter PrPSc and for 21 
conversion to take place are on the cell surface or within the endocytic pathway and it 22 
would appear reasonable to expect cofactors to reside in these locations. Results from 23 
experiments in cell lines supporting either location as a site for conversion have been 24 
published (Borchelt et al., 1992, Hooper, 2011). Recent data from our laboratories (Graham, 25 
et al., 2010, Graham, et al., 2011) and others (Abid et al., 2010), suggest that the plasma 26 
membrane is a more likely source of cofactors modulating prion protein misfolding. It is 27 
plausible that specific compositions of lipid can modulate prion protein structure thereby 28 
creating conditions for strain specific misfolding. Misfolding in or around the plasma 29 
membrane would facilitate toxic mechanisms that involve disturbances in membrane 30 
permeability. There are also various properties intrinsic to the prion protein that exert an 31 
influence on misfolding and which therefore may impact on neuronal toxicity of the 32 
resulting aggregates. Amino acid substitutions in the prion protein affect susceptibility of 33 
animals to prion disease and mutations in the human PRNP gene (encoding the prion 34 
protein) appear to be a direct cause of familial prion diseases. In general, those amino acid 35 
substitutions associated with resistance to prion disease in animals appear to decrease the 36 
stability of recombinant prion proteins in vitro (Bujdoso et al., 2005, Kirby, et al., 2010, Paludi 37 
et al., 2007, Thackray et al., 2004) potentially leading to differing levels of cellular toxicity. By 38 
contrast, there is conflicting data on the ability of mutations associated with human familial 39 
disease to affect the structure and stability of PrPC (e.g. (Apetri et al., 2004, Bae et al., 2009, 40 
Inouye et al., 2000, Rossetti et al., 2011, van der Kamp & Daggett, 2010, Vanik & Surewicz, 41 
2002, Yin et al., 2007)) and there is a lack of clear data suggesting that human mutations 42 
confer increased neurotoxicity upon misfolded PrP. It seems likely that the effects of 43 
individual amino acid changes depend on the specific substitution as well as the position 44 
within the sequence of PrPC and potentially the species that the amino acid change is in. 45 
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PrPC undergoes various post translational modifications in vivo and many have been 1 
investigated for their impact on prion protein misfolding. In transgenic mice that express 2 
prion protein lacking the C-terminal signal sequence, the GPI anchor is not attached (GPI-/-) 3 
and this results in secretion of PrPC into the extracellular milieu. When GPI-/- mice are 4 
infected with a prion disease there is dramatic accumulation of large amyloid plaques 5 
composed of anchorless PrP but no evidence of neurodegeneration (Chesebro, et al., 2005). 6 
The reasons for this are unclear but presumably result from the lack of association of PrPC 7 
with the plasma membrane (Caughey et al., 2009), however, preventing GPI anchor addition 8 
also inhibits glycosylation of PrPC and this may be a compounding factor in the lack of 9 
pathology/disease. Nevertheless, as mentioned earlier, these results further indicate that 10 
large aggregates composed of prion protein are not neurotoxic per se. 11 
N-linked glycosylation of PrPC occurs at two sites in the C-terminal region of the protein 12 
(Rudd et al., 2002) and a variety of techniques have been used to study the effect of 13 
glycosylation on prion protein misfolding. In vitro studies suggest that glycosylation of PrPC 14 
affects its interaction with PrPSc (Priola & Lawson, 2001), but that glycosylation is not 15 
required for strain properties (Nishina et al., 2006, Piro et al., 2009). Initial reports from 16 
studies in cell lines suggested that removing prion glycosylation produced spontaneously 17 
misfolded protein (Lehmann & Harris, 1997), however, this may have been a result of over-18 
expression, since more recent studies have shown that blocking glycosylation of 19 
endogenously expressed PrPC does not produce this phenotype (Cancellotti, et al., 2005). In 20 
some cases, studies have been hampered by the folding and trafficking abnormalities that 21 
can occur when PrPC is expressed without glycosylation (Cancellotti, et al., 2005, DeArmond 22 
et al., 1997) depending on the specific mutations used to prevent glycosylation (Capellari et 23 
al., 2000, Ikeda et al., 2008, Salamat et al., 2011, Wong et al., 2000b). Neuendorf et al selected 24 
deglycosylating mutations that retained authentic PrPC cellular trafficking and mice in 25 
which these proteins were over-expressed were susceptible to both scrapie and BSE 26 
(Neuendorf et al., 2004). However, in some cases, incubation times were shorter than with 27 
wild type mice, which is probably an artefact of over-expression. In our laboratories we 28 
have produced gene-targeted mice lacking prion protein glycosylation (Cancellotti, et al., 29 
2005) and analysis of these mice confirm that glycosylation is important for efficient 30 
trafficking of PrPC, but that glycosylation is not always required to sustain prion infection 31 
after intracranial inoculation (Tuzi, et al., 2008). Intra-cranial infection of these mice with 32 
multiple prion strains indicates dramatically different requirements for occupation of each 33 
of the glycosylation sites of host PrP for infection. However, since disease outcomes are 34 
significantly modulated following peripheral infection of glycosylation-deficient, gene-35 
targeted mice, our data also suggest that glycosylation of PrP is important for either 36 
peripheral replication of PrPSc or for trafficking of the infection to the CNS (Cancellotti, et 37 
al., 2010). The glycans present at either site are highly heterogeneous (Ritchie et al., 2002, 38 
Rudd et al., 1999, Stimson et al., 1999); at least 60 different glycan moieties can be present on 39 
the protein and genetic removal of glycosylation does not distinguish between individual 40 
glycan structures. Thus, it is unclear whether any individual carbohydrate chains render the 41 
prion protein particularly susceptible to misfolding. 42 
In summary, although we know the structure of PrPC to atomic resolution and we can 43 
model the conversion to PrPSc in vitro, the details of how this process takes place in vivo are 44 
still unknown. Although various factors are known to affect the way that PrPC may misfold, 45 
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the only factor absolutely known to direct this process is exogenous PrPSc. It is assumed that 1 
the PrPSc catalysed misfolding of PrPC results in a species that is neurotoxic, but it remains 2 
possible that loss of PrPC is an important process in mediating neurotoxicity. Once 3 
neurotoxicity results, it appears clear that synaptic dysfunction is one of the first 4 
pathological alterations that can be detected. Approaches that integrate studies of protein 5 
misfolding, in vitro toxicity and in vivo toxicity are required to allow us to address the many 6 
unknowns of neuronal loss in prion disease 7 
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